2-Bromo-4,5-dimethyl-benzenesulfonyl chloride | 71795-72-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Bromo-4,5-dimethyl-benzenesulfonyl chloride
• 英文别名: 2-Bromo-4,5-dimethylbenzenesulfonyl chloride
• CAS: 71795-72-7
• 化学式: C₈H₈BrClO₂S
• 分子量: 283.573
• InChiKey: LOSWVTPOIIAILQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Bromo-4,5-dimethyl-benzenesulfonyl chloride 、 邻氯苯胺 以57%的产率得到
  参考文献：
  名称：

  MAREI A.; FAM S. A.; EL SAYED M.; ABDEL SALAM F.; RASMY A., EGYPT. J. CHEM., 1976(1979), 19, NO 6, 1063-1081

  摘要：

  DOI：
• 作为产物：
  描述：

  sodium;2-bromo-4,5-dimethylbenzenesulfonate 、 五氯化磷 生成 2-Bromo-4,5-dimethyl-benzenesulfonyl chloride
  参考文献：
  名称：

  MAREI A.; FAM S. A.; EL SAYED M.; ABDEL SALAM F.; RASMY A., EGYPT. J. CHEM., 1976(1979), 19, NO 6, 1063-1081

  摘要：

  DOI：

文献信息

• [EN] 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES<br/>[FR] DÉRIVÉS DE 3-(PHÉNYLSULFONYL)- [1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE
  申请人：BIOVERSYS AG

  公开号：WO2020109350A1

  公开（公告）日：2020-06-04

  The present invention relates to a compound according to formula (I), wherein R1 and R5 are independently selected from H, halogen, hydroxyl, NO2, CN, C1-C6-alkyl optionally substituted by one or more R11, C1-C6-alkoxy optionally substituted by one or more R11, C3-C6-cycloalkyl optionally substituted by one or more R11, -Cn-alkyl-N(R12)(R13) with n=0-3, -Cn-alkyl-C(O)N(R12)(R13) with n=0-3, -SO2-N(R14)-C(O)-R15; -Cn-alkyl-N(R14)-C(O)-R15 with n=0-3, -Cn-alkyl-C(O)-OR16 with n=0-3, -O(C1-C3-alkyl-O)m-C1-C3-alkyl-OR10 with m=0-3, -Cn-alkyl-OR16 with n=0-3, -NH-Cn-alkyl-R18 with n=0-3; -O-Cn-alkyl-R18 with n=0-3; -OPO(OR10)2, -PO(OR10)2, and a heterocycle optionally substituted by one or more R17; R3 is selected from halogen, hydroxyl, NO2, CN, C1-C6-alkyl optionally substituted by one or more R11, C1-C6-alkoxy optionally substituted by one or more R11, C3-C6-cycloalkyl optionally substituted by one or more R11, -Cn-alkyl-N(R12)(R13) with n=0-3, -Cn-alkyl-C(O)N(R12)(R13) with n=0-3, -SO2-N(R14)-C(O)-R15; -Cn-alkyl-N(R14)-C(O)-R15 with n=0-3, -Cn-alkyl-C(O)-OR16 with n=0-3, -O(C1-C3-alkyl-O)m-C1-C3-alkyl-OR10 with m=0-3, -Cn-alkyl-OR16 with n=0-3, -NH-Cn-alkyl-R18 with n=0-3; -O-Cn-alkyl-R18 with n=0-3; -OPO(OR10)2, -PO(OR10)2, and a heterocycle optionally substituted by one or more R17; R2 and R4 are independently selected from H, halogen, C1-C6-alkyl optionally substituted by one or more R11; R6, R7, R8 and R9 are independently selected from H, halogen, hydroxyl, NO2, CN, C1-C6-alkyl optionally substituted by one or more R11, C1-C6-alkoxy optionally substituted by one or more R11, C3-C6-cycloalkyl optionally substituted by one or more R11, -Cn-alkyl-N(R12)(R13) with n=0-3, -Cn-alkyl-C(O)N(R12)(R13) with n=0-3, -SO2-N(R12)(R13), -SO2-N(R14)-C(O)-R15; -Cn-alkyl-N(R14)-C(O)-R15 with n=0-3, -Cn-alkyl-C(O)-OR16 with n=0-3, -O(C1-C3-alkyl-O)m-C1-C3-alkyl-OR10 with m=0-3, -Cn-alkyl-OR16 with n=0-3, -NH-Cn-alkyl-R18 with n=0-3; -O-Cn-alkyl-R18 with n=0-3; -OPO(OR10)2, -PO(OR10)2, and a heterocycle optionally substituted by one or more R17; R10 is selected from H and C1-C6-alkyl optionally substituted by one or more R11; said one or more R11 is independently selected from Cl, F and hydroxy; R12, R13, R14, R15 and R16 are independently selected from H, C1-C6-alkyl optionally substituted by one or more R11, C3-C6-cycloalkyl optionally substituted by one or more R11, -SO2-C1-C6-alkyl optionally substituted by one or more R11, or wherein said R12 and R13 together with the nitrogen to which they are attached form a heterocycle optionally substituted by one or more R17; said one or more R17 is independently selected from halogen, hydroxy, NO2, CN, -N(R12)(R13), -C(O)-R16, -C(O)-OR16, -Cn-alkyl-OR16 with n=0-3, C1-C6-alkyl optionally substituted by one or more R11, and C1-C6-alkoxy optionally substituted by one or more R11; R18 is selected from -N(R12)(R13), -OR10, -C(O)-R16, -C(O)-OR16, -C(O)- N(R12)(R13), CN, and a heterocycle optionally substituted by one or more R17; and wherein at least one of R1, R2, R4, R5, R6, R7, R8 or R9 is not H; and pharmaceutically acceptable salts, stereoisomers, enantiomers, tautomers of the compounds of formula (I) as well as pharmaceutical compositions thereof and their uses in methods of reducing the virulence of bacteria that express AgrA, in methods for preventing or treating diseases caused or exacerbated by bacteria, preferably by Staphylococcus aureus, such as skin or lung infections or atopic dermatitis.

  本发明涉及一种化合物，其符合以下式（I），其中R1和R5分别选自H、卤素、羟基、NO2、CN、C1-C6烷基（可选地由一个或多个R11取代）、C1-C6烷氧基（可选地由一个或多个R11取代）、C3-C6环烷基（可选地由一个或多个R11取代）、-Cn-烷基-N（R12）（R13）（n=0-3）、-Cn-烷基-C（O）N（R12）（R13）（n=0-3）、-SO2-N（R14）-C（O）-R15；-Cn-烷基-N（R14）-C（O）-R15（n=0-3）、-Cn-烷基-C（O）-OR16（n=0-3）、-O（C1-C3-烷基-O）m-C1-C3-烷基-OR10（m=0-3）、-Cn-烷基-OR16（n=0-3）、-NH-Cn-烷基-R18（n=0-3）；-O-Cn-烷基-R18（n=0-3）；-OPO（OR10）2、-PO（OR10）2，以及可选地由一个或多个R17取代的杂环；R3选自卤素、羟基、NO2、CN、C1-C6烷基（可选地由一个或多个R11取代）、C1-C6烷氧基（可选地由一个或多个R11取代）、C3-C6环烷基（可选地由一个或多个R11取代）、-Cn-烷基-N（R12）（R13）（n=0-3）、-Cn-烷基-C（O）N（R12）（R13）（n=0-3）、-SO2-N（R14）-C（O）-R15；-Cn-烷基-N（R14）-C（O）-R15（n=0-3）、-Cn-烷基-C（O）-OR16（n=0-3）、-O（C1-C3-烷基-O）m-C1-C3-烷基-OR10（m=0-3）、-Cn-烷基-OR16（n=0-3）、-NH-Cn-烷基-R18（n=0-3）；-O-Cn-烷基-R18（n=0-3）；-OPO（OR10）2、-PO（OR10）2，以及可选地由一个或多个R17取代的杂环；R2和R4分别选自H、卤素、C1-C6烷基（可选地由一个或多个R11取代）；R6、R7、R8和R9分别选自H、卤素、羟基、NO2、CN、C1-C6烷基（可选地由一个或多个R11取代）、C1-C6烷氧基（可选地由一个或多个R11取代）、C3-C6环烷基（可选地由一个或多个R11取代）、-Cn-烷基-N（R12）（R13）（n=0-3）、-Cn-烷基-C（O）N（R12）（R13）（n=0-3）、-SO2-N（R12）（R13）、-SO2-N（R14）-C（O）-R15；-Cn-烷基-N（R14）-C（O）-R15（n=0-3）、-Cn-烷基-C（O）-OR16（n=0-3）、-O（C1-C3-烷基-O）m-C1-C3-烷基-OR10（m=0-3）、-Cn-烷基-OR16（n=0-3）、-NH-Cn-烷基-R18（n=0-3）；-O-Cn-烷基-R18（n=0-3）；-OPO（OR10）2、-PO（OR10）2，以及可选地由一个或多个R17取代的杂环；R10选自H和C1-C6烷基（可选地由一个或多个R11取代）；所述的一个或多个R11分别选自Cl、F和羟基；R12、R13、R14、R15和R16分别选自H、C1-C6烷基（可选地由一个或多个R11取代）、C3-C6环烷基（可选地由一个或多个R11取代）、-SO2-C1-C6烷基（可选地由一个或多个R11取代），或其中所述的R12和R13与它们连接的氮一起形成一个可选地由一个或多个R17取代的杂环；所述的一个或多个R17分别选自卤素、羟基、NO2、CN、-N（R12）（R13）、-C（O）-R16、-C（O）-OR16、-Cn-烷基-OR16（n=0-3）、C1-C6烷基（可选地由一个或多个R11取代）和C1-C6烷氧基（可选地由一个或多个R11取代）；R18选自-N（R12）（R13）、-OR10、-C（O）-R16、-C（O）-OR16、-C（O）-N（R12）（R13）、CN，以及可选地由一个或多个R17取代的杂环；其中R1、R2、R4、R5、R6、R7、R8或R9中至少有一个不是H；以及所述的化合物的药学上可接受的盐、立体异构体、对映异构体、互变异构体，以及其在减少表达AgrA的细菌的毒力的方法中的药物组合物及其用途，用于预防或治疗由细菌引起或加重的疾病，优选由金黄色葡萄球菌引起的疾病，如皮肤或肺部感染或特应性皮炎。
• MAREI A.; FAM S. A.; EL SAYED M.; ABDEL SALAM F.; RASMY A., EGYPT. J. CHEM., 1976(1979), 19, NO 6, 1063-1081
  作者：MAREI A.、 FAM S. A.、 EL SAYED M.、 ABDEL SALAM F.、 RASMY A.

  DOI：——

  日期：——
• 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES
  申请人：BIOVERSYS AG

  公开号：US20220024928A1

  公开（公告）日：2022-01-27

  The present invention relates to a compound according to formula (I), wherein R1 and R5 are independently selected from H, halogen, hydroxyl, NO 2 , CN, C 1 -C 6 -alkyl optionally substituted by one or more R11, C 1 -C 6 -alkoxy optionally substituted by one or more R11, C 3 -C 6 -cycloalkyl optionally substituted by one or more R11, —C n -alkyl-N(R12)(R13) with n=0-3, —C n -alkyl-C(O)N(R12)(R13) with n=0-3, —SO 2 —N(R14)-C(O)—R15; —C n -alkyl-N(R14)-C(O)—R15 with n=0-3, —C n -alkyl-C(O)—OR16 with n=0-3, —O(C 1 -C 3 -alkyl-O) m —C 1 -C 3 -alkyl-OR10 with m=0-3, —C n -alkyl-OR16 with n=0-3, —NH—C n -alkyl-R18 with n=0-3; —O—C n -alkyl-R18 with n=0-3; —OPO(OR10) 2 , —PO(OR10) 2 , and a heterocycle optionally substituted by one or more R17; R3 is selected from halogen, hydroxyl, NO 2 , CN, C 1 -C 6 -alkyl optionally substituted by one or more R11, C 1 -C 6 -alkoxy optionally substituted by one or more R11, C 3 -C 6 -cycloalkyl optionally substituted by one or more R11, —C n -alkyl-N(R12)(R13) with n=0-3, —C n -alkyl-C(O)N(R12)(R13) with n=0-3, —SO 2 —N(R14)-C(O)—R15; —C n -alkyl-N(R14)-C(O)—R15 with n=0-3, —C n -alkyl-C(O)—OR16 with n=0-3, —O(C 1 -C 3 -alkyl-O) m —C 1 -C 3 -alkyl-OR10 with m=0-3, —C n -alkyl-OR16 with n=0-3, —NH—C n -alkyl-R18 with n=0-3; —O—C n -alkyl-R18 with n=0-3; —OPO(OR10) 2 , —PO(OR10) 2 , and a heterocycle optionally substituted by one or more R17; R2 and R4 are independently selected from H, halogen, C 1 -C 6 -alkyl optionally substituted by one or more R11; R6, R7, R8 and R9 are independently selected from H, halogen, hydroxyl, NO 2 , CN, C 1 -C 6 -alkyl optionally substituted by one or more R11, C 1 -C6-alkoxy optionally substituted by one or more R11, C 3 -C 6 -cycloalkyl optionally substituted by one or more R11, —C n -alkyl-N(R12)(R13) with n=0-3, —C n -alkyl-C(O)N(R12)(R13) with n=0-3, —SO 2 —N(R12) (R13), —SO 2 —N(R14)-C(O)—R15; —C n -alkyl-N(R14)-C(O)—R15 with n=0-3, —C n -alkyl-C(O)—OR16 with n=0-3, —O(C 1 -C 3 -alkyl-O) m —C 1 -C 3 -alkyl-OR10 with m=0-3, —C n -alkyl-OR16 with n=0-3, —NH—C n -alkyl-R18 with n=0-3; —O—C n -alkyl-R18 with n=0-3; —OPO(OR10) 2 , —PO(OR10) 2 , and a heterocycle optionally substituted by one or more R17; R10 is selected from H and C 1 -C 6 -alkyl optionally substituted by one or more R11; said one or more R11 is independently selected from Cl, F and hydroxy; R12, R13, R14, R15 and R16 are independently selected from H, C 1 -C 6 -alkyl optionally substituted by one or more R11, C 3 -C 6 -cycloalkyl optionally substituted by one or more R11, —SO 2 —C 1 -C 3 -alkyl optionally substituted by one or more R11, or wherein said R12 and R13 together with the nitrogen to which they are attached form a heterocycle optionally substituted by one or more R17; said one or more R17 is independently selected from halogen, hydroxy, NO 2 , CN, —N(R12)(R13), —C(O)—R16, —C(O)—OR16, —C n -alkyl-OR16 with n=0-3, C 1 -C 6 -alkyl optionally substituted by one or more R11, and C 1 -C 6 -alkoxy optionally substituted by one or more R11; R18 is selected from —N(R12)(R13), —OR10, —C(O)—R16, —C(O)—OR16, —C(O)—N(R12)(R13), CN, and a heterocycle optionally substituted by one or more R17; and wherein at least one of R1, R2, R4, R5, R6, R7, R8 or R9 is not H; and pharmaceutically acceptable salts, stereoisomers, enantiomers, tautomers of the compounds of formula (I) as well as pharmaceutical compositions thereof and their uses in methods of reducing the virulence of bacteria that express AgrA, in methods for preventing or treating diseases caused or exacerbated by bacteria, preferably by Staphylococcus aureus , such as skin or lung infections or atopic dermatitis.